Most Popular
-
1
Now is no time to add pressure on businesses: top executives
-
2
CJ CheilJedang to spur overseas growth with new Hungary, US plants
-
3
Seoul to host winter festival from Dec. 13
-
4
Blackpink's solo journeys: Complementary paths, not competition
-
5
Nationwide rail disruptions feared as union plans strike from Dec. 5
-
6
Korean Air offers special flights for mileage users
-
7
N. Korea, Russia court softer image: From animal diplomacy to tourism
-
8
Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
-
9
[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
-
10
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
![[Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/21/20241121050099_0.jpg&u=20241121172748)
[THE INVESTOR] Cha Biotech announced on Aug. 3 that it will collaborate with US-based Sorrento Therapeutics in developing immunotherapy.
The research will be conducted by a joint venture between the two companies.
Cha Biotech will hold 51 percent stake in the company.
Under the agreement, the two companies will collaborate in splicing the gene for chimeric antigen receptor into natural killer cells. Chimeric antigen receptor or CAR are engineered to have specificity to selected proteins.
Natural killer cells that express CAR will detect and attack only the cancer cells expressing the protein specific to CAR.
By Choi He-suk (cheesuk@heraldcorp.com)
The research will be conducted by a joint venture between the two companies.
Cha Biotech will hold 51 percent stake in the company.
Under the agreement, the two companies will collaborate in splicing the gene for chimeric antigen receptor into natural killer cells. Chimeric antigen receptor or CAR are engineered to have specificity to selected proteins.
Natural killer cells that express CAR will detect and attack only the cancer cells expressing the protein specific to CAR.
By Choi He-suk (cheesuk@heraldcorp.com)
